KYNTRA BIO, INC.
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
About Kyntra Bio
Pharmaceutical Preparations, SIC 2834
Kyntra Bio, Inc. is a biopharmaceutical company engaged in the research, clinical development, and commercialization of pharmaceutical drug candidates. The company operates through business streams that include drug product manufacturing and supply as well as research, development, and licensing arrangements. Its primary lead product candidates comprise roxadustat and FG-3246, which is developed in conjunction with the positron emission tomography imaging agent FG-3180. Its principal customers and commercial counterparties include major multinational pharmaceutical partners such as Astellas and AstraZeneca, who collaborate on product development and commercial distribution.
Geographically, the company maintains business operations, commercial relationships, and licensing arrangements across several key global markets, including the United States, Europe, Japan, and China. It also maintains corporate ties to entities located in Finland and the Cayman Islands, while executing the sale of its roxadustat business in China. Kyntra Bio is incorporated in Delaware and operates its principal executive offices in San Francisco, California.
Summary of the business section of Kyntra Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KYNTRA BIO, INC.
- Headquarters
- San Francisco, CA
- Address
- 350 Bay Street, Suite 100 #6009 94133
- Phone
- (415) 978-1200
- Employees
- 34, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Irvine, California
Stock & identifiers
- Ticker
- KYNB
- Exchange
- Nasdaq
- IPO date
- Nov 14, 2014
- Shares outstanding
- 4M, Jul 31, 2026
- Public float
- $21.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 11, 2025; 1-for-25 reverse, Jun 17, 2025
- SEC CIK
- 921299
- CUSIP
- 31572Q881
- ISIN
- US31572Q8814
- LEI
- 549300Q914ULWWY95822
- EIN
- 77-0357827
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thane Wettig | CEO, Director | 26,836 |
| David DeLucia | Chief Financial Officer | 4,355 |
| Christine Chung | SVP, CHINA OPERATIONS | 294,544 |
| Juan Graham | CHIEF FINANCIAL OFFICER | 164,863 |
| Maykin Ho | Director | 37,726 |
| Michael Kauffman | Director | – |
| James A. Schoeneck | Director | 68,432 |
| Jeffrey L. Edwards | Director | 38,601 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 First Peo | $2.11M | $1.46M | $1.15M | $2 | – |
| FY2025 Second Peo | $0 | $0 | $1.15M | $2 | – |
| FY2024 First Peo | $2.64M | $1.55M | $1.04M | $3 | – |
| FY2024 Second Peo | $0 | $0 | $1.04M | $3 | – |
| FY2023 First Peo | $3.64M | -$85.60K | $3.13M | $6 | – |
| FY2023 Second Peo | $7.44M | -$4.79M | $3.13M | $6 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We had 34 employees in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 6, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 9, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 7, 2026 | Name change | Name changed from FIBROGEN INC to KYNTRA BIO, INC. |
| Sep 5, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 17, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 16, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 27, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 14, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 12, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |